A new and simple spectrophotometric method was developed for the simultaneous determination of a new antidiabetic mixture of linagliptin and empagliflozin namely fourier self deconvulated method. The developed method based on minimal mathematical data processing on the zero order spectrum for solving sever overlapping spectra of the mentioned drugs in their pure forms and pharmaceutical dosage form. The zero order spectra of linagliptin and empagliflozin were deconvulated using Fourier transforms function. The peak amplitudes at 232 nm were selected for linagliptin and at 239 nm for empagliflozin. The constructed calibration graphs were linear over the range (5–30 µg/mL) and (2–12 µg/mL) for empagliflozin and linagliptin, respectively. The adopted method was simple, accurate, precise and validated according to the ICH guidelines.

建立了同时测定利格列汀和依帕格列净的新型抗糖尿病混合物的新方法，即分光光度法。基于零级光谱的最小数学数据处理的已开发方法，用于解决上述药物的纯形式和药物剂型的重迭光谱。利格列汀和依帕列净的零级光谱使用傅里叶变换函数进行反卷积。对于利拉列汀，选择232nm处的峰幅度，对于依帕格列净，选择239nm处的峰幅度。对于恩帕格列净和利拉列汀，所建立的校准曲线分别在（5–30 µg / mL）和（2–12 µg / mL）范围内呈线性。采用的方法简单，准确，精确，并根据ICH指南进行了验证。